Pacira Biosciences cut to hold from buy at Truist; target raised to $36.5 from $31
PCRX•Truist Securities cut its rating on Pacira Biosciences to hold from buy and raised its target price to $36.5 from $31.
Related News
Onterris, Inc. target price cut to $25 from $29
ONT•
LCR Ventures says UK health-tech founders face tougher NHS traction scrutiny as Q2 2026 biotech funding hits £2.05 billion
XLV•
Realty Income Corporation: Stifel cuts target price to $63.75 from $70.75
O•
East West Bancorp: Truist Securities cuts target price to $131 from $137
EWBC•
Cyngn autonomous fleet completes more than 11,600 missions in first nine months of 2026
CYN•